Stem definition | Drug id | CAS RN |
---|---|---|
antivirals | 5301 | 1985606-14-1 |
Dose | Unit | Route |
---|---|---|
40 | mg | O |
Property | Value | Reference |
---|---|---|
S (Water solubility) | 0.02 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 7, 2021 | EMA | ROCHE REGISTRATION GmbH | |
Oct. 24, 2018 | FDA | GENENTECH INC | |
Feb. 23, 2018 | PMDA | Shionogi & Co., Ltd. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
No adverse event | 141.54 | 48.44 | 39 | 570 | 41366 | 63447047 |
Melaena | 52.66 | 48.44 | 17 | 592 | 30348 | 63458065 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
No adverse event | 88.02 | 46.47 | 26 | 487 | 22901 | 34933517 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
No adverse event | 91.50 | 41.62 | 29 | 976 | 37163 | 79706220 |
Pneumonia | 62.21 | 41.62 | 57 | 948 | 660189 | 79083194 |
Anaphylactic reaction | 61.93 | 41.62 | 27 | 978 | 83716 | 79659667 |
Abnormal behaviour | 52.37 | 41.62 | 19 | 986 | 36402 | 79706981 |
Loss of consciousness | 52.05 | 41.62 | 30 | 975 | 167913 | 79575470 |
Colitis ischaemic | 50.56 | 41.62 | 15 | 990 | 15344 | 79728039 |
Rhabdomyolysis | 50.50 | 41.62 | 25 | 980 | 103106 | 79640277 |
Delirium febrile | 46.09 | 41.62 | 6 | 999 | 75 | 79743308 |
Erythema multiforme | 44.31 | 41.62 | 14 | 991 | 17637 | 79725746 |
None
Source | Code | Description |
---|---|---|
ATC | J05AX25 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Other antivirals |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Influenza | indication | 6142004 | DOID:8469 |
Coronavirus infection | off-label use | 186747009 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.75 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
20MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | DISCN | TABLET | ORAL | 10633397 | April 27, 2036 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
20MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | DISCN | TABLET | ORAL | 10633397 | April 27, 2036 | METHOD FOR TREATING INFLUENZA |
40MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | RX | TABLET | ORAL | 10633397 | April 27, 2036 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
40MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | RX | TABLET | ORAL | 10633397 | April 27, 2036 | METHOD FOR TREATING INFLUENZA |
80MG | XOFLUZA | GENENTECH INC | N210854 | March 18, 2021 | RX | TABLET | ORAL | 10633397 | April 27, 2036 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
80MG | XOFLUZA | GENENTECH INC | N210854 | March 18, 2021 | RX | TABLET | ORAL | 10633397 | April 27, 2036 | METHOD FOR TREATING INFLUENZA |
2MG/ML | XOFLUZA | GENENTECH INC | N214410 | Nov. 23, 2020 | RX | FOR SUSPENSION | ORAL | 10633397 | April 27, 2036 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
2MG/ML | XOFLUZA | GENENTECH INC | N214410 | Nov. 23, 2020 | RX | FOR SUSPENSION | ORAL | 10633397 | April 27, 2036 | METHOD FOR TREATING INFLUENZA |
20MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | DISCN | TABLET | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
20MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | DISCN | TABLET | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR TREATING INFLUENZA |
40MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | RX | TABLET | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
40MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | RX | TABLET | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR TREATING INFLUENZA |
80MG | XOFLUZA | GENENTECH INC | N210854 | March 18, 2021 | RX | TABLET | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
80MG | XOFLUZA | GENENTECH INC | N210854 | March 18, 2021 | RX | TABLET | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR TREATING INFLUENZA |
2MG/ML | XOFLUZA | GENENTECH INC | N214410 | Nov. 23, 2020 | RX | FOR SUSPENSION | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA |
2MG/ML | XOFLUZA | GENENTECH INC | N214410 | Nov. 23, 2020 | RX | FOR SUSPENSION | ORAL | 11306106 | Aug. 9, 2037 | METHOD FOR TREATING INFLUENZA |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
20MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | DISCN | TABLET | ORAL | Oct. 24, 2023 | NEW CHEMICAL ENTITY |
40MG | XOFLUZA | GENENTECH INC | N210854 | Oct. 24, 2018 | RX | TABLET | ORAL | Oct. 24, 2023 | NEW CHEMICAL ENTITY |
80MG | XOFLUZA | GENENTECH INC | N210854 | March 18, 2021 | RX | TABLET | ORAL | Oct. 24, 2023 | NEW CHEMICAL ENTITY |
2MG/ML | XOFLUZA | GENENTECH INC | N214410 | Nov. 23, 2020 | RX | FOR SUSPENSION | ORAL | Oct. 24, 2023 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Polymerase acidic protein | Enzyme | INHIBITOR | IC50 | 8.85 | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
505CXM6OHG | UNII |
C4688747 | UMLSCUI |
CHEMBL4297503 | ChEMBL_ID |
124081896 | PUBCHEM_CID |
DB13997 | DRUGBANK_ID |
D11021 | KEGG_DRUG |
10491 | INN_ID |
11748 | IUPHAR_LIGAND_ID |
017822 | NDDF |
782500006 | SNOMEDCT_US |
4037950 | VANDF |
1985605-59-1 | SECONDARY_CAS_RN |
2099995 | RXNORM |
294671 | MMSL |
35334 | MMSL |
d09012 | MMSL |
C000628402 | MESH_SUPPLEMENTAL_RECORD_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4102 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 31 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4104 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 31 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-583 | GRANULE, FOR SOLUTION | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-583 | GRANULE, FOR SOLUTION | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-583 | GRANULE, FOR SOLUTION | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-583 | GRANULE, FOR SOLUTION | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-828 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-828 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-860 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-860 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-860 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-860 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-877 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-877 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-877 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 32 sections |
Xofluza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-877 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 32 sections |